Targeted Nanomedicine for Breast Cancer Therapy
- 1st Edition - August 6, 2022
- Imprint: Academic Press
- Editors: Shivani Rai Paliwal, Rishi Paliwal
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 4 4 7 6 - 0
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 6 0 0 4 - 8
Targeted Nanomedicine for Breast Cancer Therapy provides a compilation of treatment approaches for breast cancer, including conventional receptor targeting methods and novel strate… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTargeted Nanomedicine for Breast Cancer Therapy provides a compilation of treatment approaches for breast cancer, including conventional receptor targeting methods and novel strategies like stimuli responsive methods and tumor micro-environment responsive strategies. This book compiles the most important information on the state-of-the-art therapeutics, including breast cancer biomarkers and design principles of bio-responsive nanosystems. Presented in two parts, sections cover basic and receptor mediated targeting approaches and examine tumor microenvironment mediated approaches. This is a useful book for pharmaceutical scientists and basic and clinical scientists working in the research area of breast cancer and drug discovery both from academics and industry.
Worldwide, breast cancer is the most common cancer in women, however, breast cancer therapy is always challenging. This book aims to help researchers remain updated on the most targeted nanomedicine research available.
Worldwide, breast cancer is the most common cancer in women, however, breast cancer therapy is always challenging. This book aims to help researchers remain updated on the most targeted nanomedicine research available.
- Highlights promising breast cancer targets to help design nanomedicines and stimuli-triggered methods for cancer imaging and treatments
- Provides in-depth exploration of targeted breast cancer therapy, along with highlights to quickly understand the most important points
- Explores cutting-edge research in the area of targeted nanomedicine and drug delivery, including nanotheranostics for breast cancer therapy
Pharmaceutical scientists, basic and clinical scientists working in the research area of breast cancer and drug discovery both from academics and industry. Those working in nanomedicine, nanobiotechnology, anti-cancer therapy, and cancer diagnosis
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Part A
- Chapter 1. Breast cancer: introduction
- Abstract
- 1.1 Introduction: background and epidemiology
- 1.2 Breast: anatomy
- 1.3 Breast: hormonal physiology
- 1.4 Breast cancer: types
- 1.5 Breast cancer: biomarker-based classification
- 1.6 Breast cancer: stages
- 1.7 Diagnostic measures for breast cancer
- 1.8 Breast cancer therapy
- 1.9 Barriers in tumor-directed drug delivery to breast cancer
- 1.10 Conclusion
- References
- Chapter 2. Basics of targeted nanodrug delivery of chemotherapeutics for breast cancer therapy
- Abstract
- 2.1 Introduction
- 2.2 Breast cancer targeting: utilization of tumor characteristics
- 2.3 Microenvironment
- 2.4 Targeted nanodrug delivery to breast cancer
- 2.5 Conclusion
- References
- Chapter 3. Molecular targets of breast cancer for targeted nanomedicine
- Abstract
- 3.1 Introduction
- 3.2 Molecular targets of breast cancer: an overview
- 3.3 Targeting human epidermal growth receptor
- 3.4 Targeting hormone receptors in breast cancer
- 3.5 Molecular targets for triple-negative breast cancer
- 3.6 Other molecular targeting strategies for breast cancer nanotherapy
- 3.7 Future challenges for targeted nanotherapy of breast cancer
- 3.8 Conclusions
- References
- Chapter 4. Current status of nanomedicine for breast cancer treatment
- Abstract
- 4.1 Introduction
- 4.2 Marketed nanoformulations
- 4.3 Nanoformulations in clinical trials
- 4.4 Advancements in preclinical research
- 4.5 Conclusions and future perspectives
- References
- Chapter 5. Targeted nanomedicine delivery to human epidermal growth receptor
- Abstract
- 5.1 Introduction
- 5.2 Pathogenesis and types of breast cancer
- 5.3 Human epidermal growth factor receptor (HER or EGFR) family tree
- 5.4 Biomarkers
- 5.5 Metastasis and breast cancer resistance
- 5.6 Nanotechnology-mediated HER-2-targeted therapeutics delivery
- 5.7 Future prospects
- References
- Chapter 6. Cell-selective breast cancer targeting through estrogen receptors
- Abstract
- 6.1 Introduction
- 6.2 Estrogen receptor-mediated targeting
- 6.3 Estrogen-based targeting strategies
- 6.4 Estrogen-mediated diagnosis
- 6.5 Conclusion and future prospects
- References
- Chapter 7. Folate receptor-mediated targeted breast cancer nanomedicine
- Abstract
- 7.1 Introduction
- 7.2 Folate structure and folic acid binding to folate receptor
- 7.3 Targeting strategies for nanoparticulate systems
- 7.4 Folate-targeted nanoparticles for breast cancer therapy
- 7.5 Conclusion
- References
- Chapter 8. Hyaluronic receptors for developing breast cancer nanomedicine
- Abstract
- 8.1 Introduction
- 8.2 Structure and function of CD44
- 8.3 Classification of breast cancer
- 8.4 Nanocarrier-based drug CD44 targeting
- 8.5 Liposomes
- 8.6 Iron oxide NPs
- 8.7 PLGA NPs
- 8.8 Gold nanocarriers
- 8.9 Micelles
- 8.10 Conjugation
- 8.11 Miscellaneous
- 8.12 Alkaloids
- 8.13 Antiinflammatory agent-mediated CD44 targeting
- 8.14 Conclusion
- Conflicts of interests
- Acknowledgment
- References
- Chapter 9. Targeting triple-negative breast cancers using nanomedicine
- Abstract
- 9.1 Introduction
- 9.2 Triple-negative breast cancer treatment availability
- 9.3 Constraints to triple-negative breast cancer therapy
- 9.4 Nanomedicines in triple-negative breast cancer: current status
- 9.5 Organic material-based nanomedicines
- 9.6 Polymer-based nanomedicines
- 9.7 Inorganic material-based nanomedicines
- 9.8 Carbon-based nanomedicines
- 9.9 Advanced nanotherapeutics for triple-negative breast cancer therapy
- 9.10 Conclusion
- Abbreviations
- Acknowledgment
- References
- Chapter 10. Tumor adhesion molecule targeting for breast cancer nanomedicine
- Abstract
- 10.1 Introduction
- 10.2 Cell adhesion molecules
- 10.3 Cell adhesion molecules in cancer prognosis
- 10.4 Cell adhesion molecules in cancer diagnosis
- 10.5 Cell adhesion molecule targeting in cancer treatment
- 10.6 Nanocarrier-associated cell adhesion molecule in breast cancer treatment
- 10.7 Conclusion and future perspectives
- References
- Chapter 11. Nanomedicine for targeting breast cancer stem cells
- Abstract
- 11.1 Introduction
- 11.2 Biologic characteristics of breast cancer stem cells
- 11.3 Signaling pathways
- 11.4 Challenges in the treatment of breast cancer stem cells
- 11.5 Nanomedicine in breast cancer stem cell therapy
- 11.6 Combination therapy to target breast cancer stem cells
- 11.7 Conclusion and future perspective
- Acknowledgments
- Conflict of interest
- References
- Part B
- Chapter 12. Tumor microenvironment-mediated targeted drug delivery to breast cancer cells
- Abstract
- 12.1 Introduction
- 12.2 Role of tumor microenvironment in breast cancer
- 12.3 Tumor microenvironment-mediated targeted drug delivery
- 12.4 Conclusion
- References
- Chapter 13. pH-responsive nanomedicine for breast cancer targeting
- Abstract
- 13.1 Introduction
- 13.2 Mechanisms of destabilization of nanosystems in response to pH
- 13.3 pH-responsive nanosystems in breast cancer therapy
- 13.4 pH-sensitive micelles in breast cancer
- 13.5 pH-sensitive polymeric nanocarriers
- 13.6 pH-sensitive core–shell nanoparticles
- 13.7 pH-sensitive liposomes
- 13.8 Conclusion
- Acknowledgment
- References
- Chapter 14. Thermosensitive liposomes for targeted breast cancer therapy
- Abstract
- 14.1 Introduction
- 14.2 Hyperthermia in breast cancer therapy
- 14.3 Thermosensitive liposomes
- 14.4 Conclusions
- References
- Chapter 15. Hypoxia mediated targeted nanomedicine for breast cancer
- Abstract
- Graphical abstract
- 15.1 Introduction
- 15.2 Breast cancer
- 15.3 Hypoxia and cancer
- 15.4 Hypoxia mediated nanomedicine for breast cancer
- 15.5 Challenges and prospects
- 15.6 Conclusion
- Acknowledgment
- References
- Chapter 16. Redox-responsive nanomedicine for breast cancer therapy
- Abstract
- 16.1 Introduction
- 16.2 Mechanism
- 16.3 Applications of various redox-responsive nanocarriers for the treatment of breast cancer
- 16.4 Conclusion
- References
- Chapter 17. Targeted breast cancer nanotheranostics
- Abstract
- 17.1 Introduction
- 17.2 Breast cancer diagnosis
- 17.3 Nanotheranostics for breast cancer
- 17.4 Ligand-based targeted nanotheranostics
- 17.5 Tumor microenvironment targeted nanotheranostics
- 17.6 Conclusion and future prospects
- References
- Chapter 18. Radionanotheranostics for breast cancer diagnosis and therapy: recent advances and future opportunities
- Abstract
- 18.1 Introduction
- 18.2 The radioisotopes used in radionanotheranostic nanomedicine
- 18.3 Types of radionanotheranostics
- 18.4 Conclusion
- 18.5 Future prospective
- Acknowledgment
- References
- Chapter 19. Cell-penetrating peptides (CPPs) and peptide-drug conjugate systems (PDCs): site-specific delivery of bioactive(s) for effective breast cancer therapy
- Abstract
- 19.1 Introduction
- 19.2 Cell-penetrating peptides and different mechanisms for their internalization
- 19.3 Cell-targeting peptide in breast cancer therapy
- 19.4 Peptide–drug conjugates in breast cancer therapy
- 19.5 Cell-penetrating peptide-based peptide–drug conjugates in breast cancer therapy
- 19.6 Conclusion and future perspective
- Acknowledgment
- References
- Further reading
- Index
- Edition: 1
- Published: August 6, 2022
- Imprint: Academic Press
- No. of pages: 562
- Language: English
- Paperback ISBN: 9780128244760
- eBook ISBN: 9780323860048
SP
Shivani Rai Paliwal
Dr. Shivani Rai Paliwa PhD has completed her doctorate from department of pharmaceutical Sciences, Dr. H. S. Gour University, Sagar, MP, India. Dr. Paliwal has experience of 10 years in teaching and research. She is recipient of many awards including Young Women Scientist Award by council of science and technology of the MP, Rudolf Cimdins Award by ESB, Switzerland, Fast Track Young Scientist Award by DST. She has published more than 35 research and review articles in international journal of high repute and authored many book chapters in edited books. She delivered talks at various national and international platforms.
Affiliations and expertise
Senior Assistant Professor, SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Viswavidyalaya (A Central University), Bilaspur, Chhattisgarh, IndiaRP
Rishi Paliwal
Dr. Rishi Paliwal PhD has completed his bachelor, master and doctorate degree in pharmacy from the Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar, MP, India which is one of prestigious and oldest pharmacy institute in India. Dr. Paliwal completed his Post Doctorate from Rangel College of Pharmacy, Texas A&M University, USA. Dr. Paliwal has contributed substantially to research on novel drug delivery, drug targeting and nanobiotechnology involving colloidal drug carriers customized for targeted drug delivery. Dr. Paliwal is a recipient of young scientist award given by Madhya Pradesh Council of Science and Technology, Bhopal for his research efforts in the area of nanomedicine and nanobiotechnology. He has contributed 14 book chapters in the leading international books of material sciences, nanoscience and pharmaceutical sciences. Dr. Paliwal serves as reviewer of many international journals.
Affiliations and expertise
Assistant Professor, Department of Pharmacy, IGNTU, Amarkantak, MP, IndiaRead Targeted Nanomedicine for Breast Cancer Therapy on ScienceDirect